ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS, vytvořeno v 2005 (United States), z 496 sesterských značek a 17478 konkurenčních značek. Značku ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS vlastní BRISTOL-MYERS SQUIBB COMPANY, společnost kótovaná na burze v New York. Odvětvím ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS je Výrobci léků.

ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS je značkou BRISTOL-MYERS SQUIBB COMPANY (BMY). Novinky

Mezinárodní vklad: 2005 Podnikatelský sektor Výrobci léků

Všechny novinky Logo Marketscreener
BRISTOL-MYERS SQUIBB COMPANY (ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS)

loader
Burza cenných papírů: Více informací o BRISTOL-MYERS SQUIBB COMPANY (ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS) Logo Marketscreener